—
DIANT Pharma Inc., a Connecticut-based pharmacy equipment manufacturing company known for its continuous nanoparticle and LNP processing systems, has recently announced the launch of its new nanoparticle research system.
In an August 2024 press release published on the company’s website, the DIANT® LARU Discovery is described as featuring “patented turbulent jet technology” and allows for lowest volume research test runs for the multi-mode specification and optimization of nanoparticle processing.
This is a continuation of DIANT’s approach to nanoparticle continuous processing. The company’s systems, including commercial scale and R&D, are known to have state-of-the-art, highest-yield process controls. These processing systems are both novel and linear scalable, and are used widely within the industry across numerous different applications.
DIANT, which was licensed by the University of Connecticut for its continuous nanoparticle manufacturing technology in 2020, has launched the LARU Discovery to address the specific needs of research applications. The Discovery is a low-volume system and has been deliberately designed to support research processes in academia and industry settings.
The CEO of DIANT Pharma Inc., Dr. Antonio Costa, explained that the LARU Discovery had been manufactured “in close collaboration” with the company’s customers, adding that they had identified the necessity to downscale their research unit, LARU, in response to the evolving needs of their client base.
According to Dr. Costa, the LARU Discovery allows DIANT to continue to maintain scalability across its product line, with its latest innovation efforts leading to the production of this low-volume processing system.
Describing the system, he said: “It incorporates the same highly efficient and precise turbulent mixing technology but at a reduced flow rate and hold-up volume. The positive feedback from our customers and stakeholders indicates that we have effectively met their demands once again.“
The DIANT LARU Discovery system has a small footprint, making it ideal for laboratory settings with less available space. The compact system can still be used at minimum collection volumes and provides a flexible testing and processing solution for a range of fluid and mixing modalities.
The system is fully scalable to DIANT’s large volume processing system such as the CGMP-compliant LiFT system, and is ideal for running feasibility studies to determine the optimal operating parameter and fluid compositions at the lowest hold-up volumes.
DIANT’s other key product is the DIANT Lift, a commercial system for the continuous production of lipid and polymer-based nanoparticle products, which can scale up processes from the LARU system and is a more efficient solution to traditional batch processing in the lipid nanoparticle manufacturing process.
About DIANT Pharma Inc
DIANT® Pharma is headquartered in Connecticut and was formed in 2019 after years of extensive research at the University of Connecticut.
The company manufactures unique, innovative continuous processing systems for vaccines and therapeutics using nanoparticles. Its aim is to use continuous manufacturing to “disruptively transform LNPs” by speeding up their production, making processing more efficient, and reducing the risks involved—ultimately helping companies to reduce their time-to-market and maximize their profits.
Contact Info:
Name: Mike Hassy
Email: Send Email
Organization: Diantpharma
Website: https://diantpharma.com/
Release ID: 89142019
Google
RSS